BTBD17
BTB/POZ domain-containing protein 17
Also known as: BTBD17A, BTBDH_HUMAN, LGALS3BPL, TANGO10A
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- A6NE02
- Gene
- BTBD17
- Ensembl
- ENSG00000204347
- Chromosome
- 17
- Canonical length
- 478 aa
- Protein class
- Predicted secreted proteins
- Subcellular location
- Cytosol
- Secretome location
- Secreted in brain
OverviewNCBI Gene
Predicted to be involved in negative regulation of viral genome replication and response to virus. Predicted to be located in cytoplasm and plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
478 residues, UniProt reviewed canonical sequence.
>A6NE02|BTBD17
1 MPRRGYSKPG SWGSFWAMLT LVGLVTHAAQ RADVGGEAAG TSINHSQAVL QRLQELLRQG
61 NASDVVLRVQ AAGTDEVRVF HAHRLLLGLH SELFLELLSN QSEAVLQEPQ DCAAVFDKFI
121 RYLYCGELTV LLTQAIPLHR LATKYGVSSL QRGVADYMRA HLAGGAGPAV GWYHYAVGTG
181 DEALRESCLQ FLAWNLSAVA ASTEWGAVSP ELLWQLLQRS DLVLQDELEL FHALEAWLGR
241 ARPPPAVAER ALRAIRYPMI PPAQLFQLQA RSAALARHGP AVADLLLQAY QFHAASPLHY
301 AKFFDVNGSA FLPRNYLAPA WGAPWVINNP ARDDRSTSFQ TQLGPSGHDA GRRVTWNVLF
361 SPRWLPVSLR PVYADAAGTA LPAARPEDGR PRLVVTPASS GGDAAGVSFQ KTVLVGARQQ
421 GRLLVRHAYS FHQSSEEAGD FLAHADLQRR NSEYLVENAL HLHLIVKPVY HTLIRTPKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against BTBD17 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 7.1 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 7.1 nTPM
- hypothalamus: 4.3 nTPM
- amygdala: 4.1 nTPM
- basal ganglia: 4.1 nTPM
- cerebellum: 3.8 nTPM
- midbrain: 3.4 nTPM
Single-cell type
- bergmann glia: 29 nCPM
- oligodendrocyte progenitor cells: 9.8 nCPM
- astrocytes: 9.6 nCPM
- retinal horizontal cells: 8 nCPM
- pancreatic islet cells: 7.5 nCPM
- late spermatids: 6.4 nCPM
Immune cell
- naive CD4 T-cell: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- hypothalamus: 15 nTPM
- midbrain: 8.5 nTPM
- thalamus: 7.6 nTPM
- pons: 6.9 nTPM
- amygdala: 6.8 nTPM
- basal ganglia: 6.5 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.78
- gnomAD pLI
- 0.02
- gnomAD missense Z
- 2.37
- DepMap mean gene effect
- -0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads BTBD17 as an antibody target. Whether an autoantibody or antibody against BTBD17 could matter depends on whether native BTBD17 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
BTBD17 is annotated as secreted, so native BTBD17 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label BTBD17 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...